These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
47. Drug Insight: endothelin-receptor antagonists for pulmonary arterial hypertension in systemic rheumatic diseases. Humbert M; Simonneau G Nat Clin Pract Rheumatol; 2005 Dec; 1(2):93-101. PubMed ID: 16932638 [TBL] [Abstract][Full Text] [Related]
48. An update on the use of ambrisentan in pulmonary arterial hypertension. D'Alto M Ther Adv Respir Dis; 2012 Dec; 6(6):331-43. PubMed ID: 22933513 [TBL] [Abstract][Full Text] [Related]
49. Endothelin receptor antagonists for the treatment of pulmonary artery hypertension. Rubin LJ Life Sci; 2012 Oct; 91(13-14):517-21. PubMed ID: 22884806 [TBL] [Abstract][Full Text] [Related]
50. [Specific drugs for the treatment of pulmonary arterial hypertension - current status]. Stähler G Dtsch Med Wochenschr; 2008 Oct; 133 Suppl 6():S183-6. PubMed ID: 18814092 [TBL] [Abstract][Full Text] [Related]
51. The importance of sex in pulmonary hypertension. Rich S Chest; 2012 Jan; 141(1):4-5. PubMed ID: 22215821 [No Abstract] [Full Text] [Related]
52. CYP2C9, SLCO1B1, SLCO1B3, and ABCB11 polymorphisms in patients with bosentan-induced liver toxicity. Roustit M; Fonrose X; Montani D; Girerd B; Stanke-Labesque F; Gonnet N; Humbert M; Cracowski JL Clin Pharmacol Ther; 2014 Jun; 95(6):583-5. PubMed ID: 24842639 [TBL] [Abstract][Full Text] [Related]
53. An evidence-based approach to the management of pulmonary arterial hypertension. Coyne TC Curr Opin Cardiol; 2006 Sep; 21(5):526; author reply 526-7. PubMed ID: 16900019 [No Abstract] [Full Text] [Related]
54. Bioactivation of sitaxentan in liver microsomes, hepatocytes, and expressed human P450s with characterization of the glutathione conjugate by liquid chromatography tandem mass spectrometry. Erve JC; Gauby S; Maynard JW; Svensson MA; Tonn G; Quinn KP Chem Res Toxicol; 2013 Jun; 26(6):926-36. PubMed ID: 23721565 [TBL] [Abstract][Full Text] [Related]
56. Hepatotoxicity by bosentan in a patient with portopulmonary hypertension: a case-report and review of the literature. Eriksson C; Gustavsson A; Kronvall T; Tysk C J Gastrointestin Liver Dis; 2011 Mar; 20(1):77-80. PubMed ID: 21451802 [TBL] [Abstract][Full Text] [Related]
58. Successful switch to sitaxsentan in a patient with HIV-related pulmonary arterial hypertension and late intolerance to nonselective endothelin receptor blockade. Zacà V; Metra M; Danesi R; Lombardi C; Verzura G; Dei Cas L Ther Adv Respir Dis; 2009 Feb; 3(1):11-4. PubMed ID: 19293198 [TBL] [Abstract][Full Text] [Related]